search
Back to results

Microparticles in Cirrhosis and Portal Hypertension (MicroCir)

Primary Purpose

Liver Cirrhosis, Portal Hypertension

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
research on interactions between portal hypertension and microparticles
Sponsored by
Centre Hospitalier Universitaire de Besancon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Liver Cirrhosis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Non infected cirrhotic patient (30 patients Child-Pugh A, 30 Child-Pugh B et 30 Child-Pugh C).
  • 10 heathly volunteer (groupe contrôle).

Exclusion Criteria:

  • legal incapacity or limited legal capacity
  • Subject unlikely to cooperate in the study and / or low early cooperation by the investigator
  • Subject without health insurance
  • Pregnant woman
  • About being in the disqualification of another study or under the "national register of volunteers."
  • Any proven or suspected infection
  • Pre-hepatic portal hypertension (door thrombosis) or post-liver (Budd-Chiari) transplant patients, HIV infection (also refusing HIV status) or patients on immunosuppressive therapies (including corticosteroids) interferon taken
  • Treatment with anticoagulants or antiplatelet upper gastrointestinal bleeding in the two months prior
  • Patients with TIPS
  • Any cancer pathology proven and current.
  • Chronic heart failure (stage III or IV of the classification of the New York Heart Association [NYHA])
  • Inability to receive clear information in patients with severe encephalopathy and do not have someone you trust

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    cirrhotic patients

    healthy volunteers

    Arm Description

    We prospectively included 90 cirrhotic patients .

    The pilot cohort was compared with 10 healthy volunteers.

    Outcomes

    Primary Outcome Measures

    Level of expression of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
    Procoagulant activity of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.

    Secondary Outcome Measures

    Full Information

    First Posted
    July 28, 2016
    Last Updated
    August 4, 2016
    Sponsor
    Centre Hospitalier Universitaire de Besancon
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02859610
    Brief Title
    Microparticles in Cirrhosis and Portal Hypertension
    Acronym
    MicroCir
    Official Title
    Characterization of Microparticles in Cirrhosis and Portal Hypertension With Implications
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2014 (undefined)
    Primary Completion Date
    January 2015 (Actual)
    Study Completion Date
    January 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Centre Hospitalier Universitaire de Besancon

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    research on interactions between portal hypertension and microparticles
    Detailed Description
    It has already been shown that increased certain markers of stress, such as prolonged elevation of CRP in the absence of bacterial infection, increased free cortisol and serum copeptin, are associated with an excess of mortality in cirrhosis. MPs are membrane vesicles of variable size between 0.1 and 1 .mu.m, released into the extracellular space following activation or cellular apoptosis. MPs are also found in the circulating blood of healthy volunteers and their plasma levels rise in certain diseases to increased thrombotic risk, such as in cancer. Their membrane is composed of antigens whose organization is characteristic of the parent cell and negatively charged phospholipids, phosphatidylserines, conferring pro-coagulant properties to these MPs. Currently, work on the MPs are increasing following the discovery of their involvement in physiological processes such as proliferation, differentiation, cell activation and immune response but it is certainly their pro-thrombogenic power that was the most studied. Recent studies have also implicated MPs in the pathophysiology of chronic liver disease. Cirrhotic patients have elevated concentrations of MPs from leukocytes, endothelial cells and hepatocytes compared to control subjects, and concentrations of MPs increase with worsening liver function. Increasing MPs during the cirrhosis may be related on the one hand with a decreased clearance and secondly with an excess of proinflammatory cytokines by increasing the phenomenon of intestinal bacterial translocation. The assumption of the role of systemic inflammation in the training of MPs is reinforced by the existence of a significant correlation between the original MPs hepatocyte or buffy endothelial and CRP Thus, the increase in MPs observed with the increase of PH could increase the risk of thrombosis in intestinal microcirculation leading to enterocytic suffering from ischemic, reflected by an increase in serum concentrations of I-FABP ( intestinal fatty acid binding protein). This suffering enterocytes leads to increased intestinal bacterial translocation and ultimately to increased formation of MPs. These MPs could also worsen liver function by the same phenomenon of thrombosis in the hepatic microcirculation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Liver Cirrhosis, Portal Hypertension

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    100 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    cirrhotic patients
    Arm Type
    Other
    Arm Description
    We prospectively included 90 cirrhotic patients .
    Arm Title
    healthy volunteers
    Arm Type
    Other
    Arm Description
    The pilot cohort was compared with 10 healthy volunteers.
    Intervention Type
    Other
    Intervention Name(s)
    research on interactions between portal hypertension and microparticles
    Primary Outcome Measure Information:
    Title
    Level of expression of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
    Time Frame
    one year
    Title
    Procoagulant activity of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
    Time Frame
    one year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Non infected cirrhotic patient (30 patients Child-Pugh A, 30 Child-Pugh B et 30 Child-Pugh C). 10 heathly volunteer (groupe contrôle). Exclusion Criteria: legal incapacity or limited legal capacity Subject unlikely to cooperate in the study and / or low early cooperation by the investigator Subject without health insurance Pregnant woman About being in the disqualification of another study or under the "national register of volunteers." Any proven or suspected infection Pre-hepatic portal hypertension (door thrombosis) or post-liver (Budd-Chiari) transplant patients, HIV infection (also refusing HIV status) or patients on immunosuppressive therapies (including corticosteroids) interferon taken Treatment with anticoagulants or antiplatelet upper gastrointestinal bleeding in the two months prior Patients with TIPS Any cancer pathology proven and current. Chronic heart failure (stage III or IV of the classification of the New York Heart Association [NYHA]) Inability to receive clear information in patients with severe encephalopathy and do not have someone you trust

    12. IPD Sharing Statement

    Learn more about this trial

    Microparticles in Cirrhosis and Portal Hypertension

    We'll reach out to this number within 24 hrs